Matched pairs for radionuclide-based imaging and therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue SUPPL. 1, 2011, Pages

  Bockisch, Andreas ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 124; IODINE 131; RADIOACTIVE IODINE; YTTRIUM 86; YTTRIUM 90;

CANCER THERAPY; DRUG HALF LIFE; GAMMA RADIATION; IMAGE QUALITY; IODINATION; NUCLEAR MEDICINE; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOISOTOPE DIAGNOSIS; RADIOISOTOPE THERAPY; REVIEW; SCINTILLATION CAMERA; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; THYROID DISEASE;

HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YTTRIUM RADIOISOTOPES;

EID: 79953752603     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1780-6     Document Type: Review

References (25)

1. S Hertz A Roberts 1942 Application of radioactive iodine in therapy of Gravés disease J Clin Invest 21 1 31 32 16694888 10.1172/JCI101276 1:CAS:528:DyaH38XosFek
2. M Dietlein J Dressler F Grünwald B Leisner E Moser C Reiners, et al. 2007 Guideline for radioiodine therapy for benign thyroid diseases (version 4) Nuklearmediziner 46 5 220 223 1:STN:280:DC%2BD2snltlynsQ%3D%3D (Pubitemid 47612289)
3. MP Stokkel D Handkiewicz Junak M Lassmann M Dietlein M Luster 2010 EANM procedure guidelines for therapy of benign thyroid disease Eur J Nucl Med Mol Imaging 37 11 2218 2228 20625722 10.1007/s00259-010-1536-8
4. A Bockisch T Jamitzky R Derwanz HJ Biersack 1993 Optimized Dose Planning of Radioiodine Therapy of Benign Thyroidal Disease J Nucl Med 34 1632 1638 8410273 1:STN:280:DyaK2c%2FhsFCisg%3D%3D (Pubitemid 23295369)
5. 86Y]yttrium. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011- 1782-4.
6. JC Reubi H Maecke 2008 Peptide-based probes for cancer imaging J Nucl Med 49 1735 1738 18927341 10.2967/jnumed.108.053041 1:CAS:528:DC%2BD1cXhsVOhtLbP
7. C Decristoforo R Knopp E von Guggenberg M Rupprich TH Dreger A Hess, et al. 2007 A fully automated synthesis for the preparation of 68Ga-labelled peptides Nucl Med Commun 28 870 875 17901771 10.1097/MNM.0b013e3282f1753d 1:CAS:528:DC%2BD2sXhtFSnt7rL (Pubitemid 47494113)
8. G Stöcklin 1977 Bromine-77 and iodine-123 radiopharmaceuticals Int J Appl Radiat Isot 28 131 47 323157 10.1016/0020-708X(77)90167-3 (Pubitemid 8089055)
9. 131I therapy of thyroid cancer. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1769-1.
10. R Bolton 2002 Radiohalogen incorporation into organic systems J Labelled Comp Radiopharm 45 485 528 10.1002/jlcr.575 1:CAS:528:DC%2BD38XksVWrtrg%3D (Pubitemid 34587075)
11. W Jentzen R Weise J Kupferschläger L Freudenberg W Brandau R Bares, et al. 2008 Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems Eur J Nucl Med Mol Imaging 35 3 611 623 17929014 10.1007/s00259-007-0554-7 (Pubitemid 351661669)
12. W Jentzen 2010 Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging Phys Med Biol 55 8 2365 2398 20360631 10.1088/0031-9155/55/8/016
13. 86Y with PET. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011- 1768-2.
14. Ritt P, Vija H, Hornegger J, Kuwert T. Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1770-8.
15. 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1773-5.
16. 90Y antibodies. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1772-6.
17. R Lhommel P Goffette M Van den Eynde F Jamar S Pauwels JI Bilbao, et al. 2009 Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT Eur J Nucl Med Mol Imaging 36 10 1696 19618182 10.1007/s00259-009- 1210-1
18. PS Conti C White P Pieslor A Molina J Aussie P Foster 2005 The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry J Nucl Med 46 1812 1818 16269594 1:CAS:528:DC%2BD28XitVGltL8%3D (Pubitemid 46196642)
19. 90Y imaging? Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1771-7.
20. L Bodei G Pepe G Paganelli 2010 Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues Eur Rev Med Pharmacol Sci 14 4 347 351 20496546 1:STN:280:DC%2BC3czlvVGltw%3D%3D
21. A Deleporte P Flamen A Hendlisz 2010 State of the art: radiolabeled microspheres treatment for liver malignancies Expert Opin Pharmacother 11 4 579 586 20163269 10.1517/14656560903520916
22. HN Wagner Jr GA Wiseman CS Marcus HA Nabi CE Nagle DM Fink-Bennett, et al. 2002 Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody J Nucl Med 43 2 267 272 11850494 1:CAS:528:DC%2BD38XjvFWjt74%3D (Pubitemid 34151052)
23. Konijnenberg M, de Jong M. Preclinical animal research on therapy dosimetry with dual isotopes. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1774-4.
24. LS Freudenberg W Jentzen T Petrich C Frömke RJ Marlowe T Heusner, et al. 2010 Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons Eur J Nucl Med Mol Imaging 37 2267 2276 20661558 10.1007/s00259-010-1565-3 1:CAS:528:DC%2BC3cXhtl2isrjE
25. W Jentzen R Hobbs A Stahl J Knust G Sgouros A Bockisch 2010 Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer Eur J Nucl Med Mol Imaging 37 884 895 20069293 10.1007/s00259-009-1351-2 1:CAS:528:DC%2BC3cXkslakt7Y%3D